

**ONE / NEXUS**

Digitalization of all radiology processes



RIS



PACS  
(CHILI)



Teleradiology  
(CHILI)



Referring  
physician portal  
(CHILI)



Quality Management  
(CURATOR)

**ONE  
NEXUS**

# Quarterly report

01<sup>ST</sup> OF JANUARY TO 31<sup>ST</sup> OF MARCH 2019

# Letter to Our Stockholders

Dear Stockholders:

Digitalization in the healthcare sector is currently moving more into the focus of patients, doctors, hospital management and, in particular, politicians in many European countries. This is a development that suggests that Germany and other European core countries want to catch up in this area. Against this background, the outlook in our industry remains very promising.

This is matched by the fact that NEXUS can already present extremely positive results today as was the case in recent years too. In the first quarter of 2019, we were able to significantly increase both sales and earnings, thus continuing our long-term development.

The increase in sales amounted to approx. 11% in the first quarter compared with the previous year. Earnings before taxes and interest increased by approx. 18% and EBITDA reached around EUR 7.5 million in the first quarter, resulting in an EBITDA margin of 21% (including the amended IFRS effects). Operating cash flow amounted to approx. EUR 26.2 million, and consequently was significantly higher than the level in the previous year. The reason behind this are the special effects of the acquisition of Swisslab DITS GmbH, Berlin. As a result, our cash and cash equivalents increased to approx. EUR 51.4 million as of 30 March 2019.

The strong figures are mainly due to our product generation NEXUS/ NEXT GENERATION, the ONE/NEXUS initiative and the stable

development in NEXUS Switzerland. We are particularly pleased that the NEXUS/NEXT GENERATION (NG) software is rated very positively on the market, which is clearly reflected in the increasing order intake and sales figures.


We launched a complementary organizational and product initiative with "ONE/NEXUS" at the end of 2018. We have continued to orientate our company organization in a market-oriented manner and centralized sales in the respective country organizations. At the same time, we will continue to internationalize our diagnostic products and combine some special software modules into new, integrated process solutions. As a result, we expect to be able to exploit new "cross-selling potential" on the market. These are important steps that will initiate our next phase of growth.

## Highlights Q1 2019 – Company development

- + Strong increases in sales in the 1st quarter
- + Increasing demand for NEXUS/ New Generation solutions
- + Laboratory/Pathology software: Link results in new orders
- + Important major projects and internationalization implemented


## Development of Group Sales (3 months) in KEUR

2008-2019



# Development of Group Earnings before Interest and Taxes (3 months) KEUR

2008-2019



Sales in Q1 2019 enabled us to acquire a large number of new and interesting projects both domestically and abroad. This applies in particular to NEXUS/HISng projects in Germany, Switzerland and Poland. The order development in NEXUS/Pathology should also be emphasized. The link with our newly acquired laboratory system "Swisslab" has already resulted in numerous new orders in the first quarter.

On the project side, we have reached very important milestones in the major orders "Bundeswehr" (German military), "Deutsche Rentenversicherung" (German pension insurance) and in particular in the Swiss "Hirslanden Kliniken" (Hirslanden Hospitals). We put our first fully integrated medication solution into productive operation in the Netherlands. This is an important step in the further internationalization of our radiological software.

The first quarter only developed slightly in our innovation project "ENDOBASE NEXT". The reason is that the new Endobase release was planned for April and therefore no new installations were implemented with the previous release. With the new release, we already expect new sales in May.

**Dr. Ingo Behrendt**  
Chief Executive Officer



The first quarter was on track in the "Healthcare Service" sector. We already dealt with the organizational challenges in this area last year and see significant progress in terms of customer satisfaction. The profitability of the sector still needs to improve in the coming months, but we have made significant progress compared to last year.

The development of the new subsidiary Swisslab GmbH, Berlin, is very positive. While the restructuring is ongoing as part of the planning, customer responses to NEXUS involvement in this laboratory area are unexpectedly positive. The product synergies between Swisslab laboratory products and NEXUS/Pathology and NEXUS/QM products are very attractive for customers. Customers also see great advantages for their Swisslab installations in the area of technical synergies (e.g., for interfaces or development frameworks).

Dear Stockholders, NEXUS is in good shape in a dynamically developing market. Healthy, long-lasting growth, good earnings development and a consistent product strategy are convincing arguments for our further course. We must not deviate from this if we are to succeed in a changing, competitive environment.

We want to thank you, dear Stockholders, for your trust.

Warm regards,

Dr. Ingo Behrendt  
Chief Executive Officer

# FINANCIAL HIGHLIGHTS

## 1<sup>ST</sup> QUARTER 2019 AND 2018

	31/03/19	31/03/18	Change
SALES AND OPERATING RESULT	KEUR	KEUR	(in %)
Sales	35,465	32,044	10.7
Healthcare Software Sales	33,316	29,511	12.9
Healthcare Service Sales	2,149	2,533	-15.2
Domestic sales	17,604	16,661	5.7
Sales in foreign countries	17,861	15,383	16.1
Earnings before tax on income (EBT)	3,823	3,253	17.5
Earnings before interest and taxes (EBIT)	3,882	3,293	17.9
EBITA	4,772	4,021	18.7
EBITDA (unadjusted for IFRS 16 effect)	7,548	5,792	30.3
EBITDA (adjusted for IFRS 16 effect)	6,755	5,792	16.6
Consolidated surplus	2,855	2,511	13.7
Cash flow from current business transactions	26,233	17,285	51.8
Net income per share (undiluted/diluted) in EUR	0.18 / 0.18	0.17 / 0.17	5.9 / 5.9
Share price (closing price, XETRA) in EUR	23.70	25.10	-5.6
Capitalization of software developments	905	1,171	-22.7
Depreciation	3,666	2,499	46.7
Acquisition-related depreciations from purchase price allocation	890	728	22.3
Fixed Assets (without deferred taxes)	129,526	122,631 <sup>1)</sup>	5.6
Current Assets / Short-Term Assets	91,800	72,920	25.9
Net Liquidity	51,444	38,559	33.4
Equity Capital	110,714	108,325 <sup>1)</sup>	2.2
Employees	1,270	1,077	17.9

<sup>1)</sup> Key date 31/12/2018

# Interim Annual Report

## REPORT ABOUT THE PROFIT, FINANCIAL AND ASSET SITUATION

NEXUS Group sales increased from KEUR 32,044 to KEUR 35,465 (+10.7%) in the first three months of the year 2019. The stable, positive sales development of NEXUS Group of recent years could be continued with that. This succeeded despite the refocusing of the Healthcare Service Division. In this segment, sales of KEUR 2,149 were achieved after KEUR 2,533 (3M-2018), i.e., approx. 15.2% less than in the previous year. The reason behind this is that we reoriented the division in 2018 and in this context also discontinued projects that are not part of the core business.

On the other hand, sales increased from KEUR 29,511 (3M-2018) to KEUR 33,316 (+12.9%) in the Healthcare Software Division. Approx. 4.5% of this increase in sales is attributable to the consolidation of Swisslab DITS GmbH acquired on 30 November 2018.

We respect to the regional development of sales, we were able to increase sales in Germany by 5.7% to KEUR 17,604 (3M-2018: KEUR 16,661). In international business, we achieved sales of KEUR 17,861 in the first quarter 2019 compared to KEUR 15,383 in the previous year (+16.1%). The main reason for this development is the strong business development in Switzerland.

Consolidated earnings before income taxes and interest (EBIT) developed very positively. They improved by 17.9% to KEUR 3,882 (3M-2018: KEUR 3,293). A value of KEUR 4,772 was achieved in EBITA and consequently was 18.7% above the value of previous year (3M-2018: KEUR 4,021). EBITDA reached KEUR 7,548 in the first quarter of 2019 (3M-2018: KEUR 5,792) and consequently was 30.3% higher than in the previous year. EBITDA includes the effects from the initial application of IFRS 16 in the amount of KEUR 793. Without this application, EBITDA would have increased from KEUR 5,792 to KEUR 6,755 (+16.6%). Non-recurring costs for integration of the new companies in the first quarter 2019 amounted to approximately TEUR 410.

The cash flow from on-going business transactions also de-velop very well. We achieved a value of KEUR 26,233 (3M-2018: KEUR 17,285) there. The main reason for the strong cash flow in the first quarter is the high deposits from maintenance revenues and the settlement of receivables in connection with the restructuring of Swisslab DITS GmbH.

The consolidated surplus increased by 13.7% and amounted to KEUR 2,855 for the first quarter 2019 following KEUR 2,511 (3M-2018). There is a slight increase in the tax rate there. The undiluted earnings per share amounted to 18 cents (previous year: 17 cents) (diluted: 18 cents; previous year: 17 cents).

Cash resources including short-term financial assets amounted to KEUR 51,444 on 31 March 2019 (31 March 2018: KEUR 38,559). Investments in tangible and intangible assets were made in the amount of KEUR 948 in the first quarter 2019

(3M-2018: KEUR 2,085). This includes KEUR 905 (3M-2018: KEUR 1,171) for capitalizing software developments.


The balance sheet total increased from KEUR 211,708 to KEUR 224,735 compared to 31 December 2018. Intangible assets, goodwill and balanced-out deferred taxes add up to a total of KEUR 106,514 following KEUR 108,712 (31 December 2018). Receivables from customers amount to KEUR 29,896 following KEUR 25,980 on 31 December 2018.

### Employees

NEXUS Group employed a total of 1,270 people as of 31 March 2019 (31 March 2018: 1,077 employees).


### EBITDA (3 MONTHS) IN KEUR

adjusted for IFRS 16 effect +16.6 % (unadjusted: +30.3 %) in comparison to the previous year



### CASH FLOW FROM CURRENT BUSINESS TRANSACTIONS (3 MONTHS) IN KEUR

+51.8 % compared to previous year



## Effect from the application of IFRS 16

The initial application of IFRS 16 broadens the depiction of leasing relations, which affects the presentation of the Group's profit, financial and asset situation.

The effects of IFRS 16 as at 31 March 2019 lead to a corresponding increase in fixed assets of KEUR 8,594 as a result of the right of use to be capitalized and to an increase in lease liabilities of KEUR 8,609 (long-term: KEUR 5,318; short-term: KEUR 3,291). The balance sheet total increases accordingly by these values and consequently by 4.0 percentage points; the equity ratio decreases by 2.0 percentage points as result. The net debt ratio has increased accordingly. The total leasing expenses in the amount of KEUR 793 – instead of other operating expenses – are recognized in the amount of KEUR 763 in depreciation and in the amount of KEUR 30 in interest expense. This results in significant improvement of EBITDA of KEUR 793.

The cash flow statement includes the redemption share of the lease payments in the cash flow from financing activities, while interest payments are included in the cash flow from current activities. This improves the cash flow of current operations by KEUR 447.

## Finance Highlights Q1 2019

- + 10.7% sales increase in first quarter 2019 from KEUR 32,044 (3M-2018) to KEUR 35,465
- + 17.9% increase in the Group result for earnings before interest and taxes (EBIT) from KEUR 3,293 (3M-2018) to KEUR 3,882
- + Continued very strong operational cash flow in the first quarter of KEUR 26,233
- + High net liquidity of KEUR 51,444

## Events after the Balance Sheet Date

There were no events requiring reporting after the balance sheet key date.

## Annual Stockholders Meeting and Dividends

At the Annual Stockholders Meeting of NEXUS AG in Donaueschingen on 3 May 2019, the Executive Board and Supervisory Board proposed to pay a one cent higher dividend of EUR 0.17 to shareholders than the previous year from the net earnings of fiscal year 2018.

## SALES BY REGION

	01/01-31/03/2019	01/01-31/03/2018	Change
	KEUR	KEUR	%
Germany	17,604	16,661	5.7
Switzerland	10,160	7,821	29.9
Netherlands	3,400	3,310	2.7
France	1,428	1,436	-0.6
Austria	669	745	-10.2
Other countries	2,204	2,071	6.4
<b>TOTAL</b>	<b>35,465</b>	<b>32,044</b>	<b>10.7</b>

## SALES BY DIVISION

	01/01-31/03/2019	01/01-31/03/2018	Change
	KEUR	KEUR	%
Healthcare Software	33,316	29,511	12.9
Healthcare Service	2,149	2,533	-15.2
<b>TOTAL</b>	<b>35,465</b>	<b>32,044</b>	<b>10.7</b>

# CAPITAL MARKET, EVENT AND FINANCE DATA

## INVESTOR RELATIONS

Active communication with our stockholders, potential investors, analysts and the finance market are the focal point of our investor relation activities. We continually inform all market participants promptly and comprehensively via press releases and ad hoc announcements as well as the mandatory quarterly, semi-annual and annual financial reports.

In addition, we cultivate intensive dialog with institutional investors and finance analysts via one-on-one meetings and on roadshows. Our Investor Relations team is of course at your disposal as contact persons.

### 03 May 2018

Quarterly Report Q1 / 2018  
.....

### 13 August 2019

Semi-Annual Report 2019  
.....


### 05 November 2019

Quarterly Report Q3 / 2019  
.....

### 25 – 27 November 2019

Analyst Event, Frankfurt

## Frankfurt Stock Exchange stock prices (5-year period)



## Stock Market Highlights (XETRA closing prices)

- + Initial listing on  
02 January 2019: 24.20 €
- + Highest price on  
06 January 2019: 26.80 €
- + Stock market capitalization on  
29 March 2019: 373.3 million €

### 21 May – 23 May 2019

Paris Healthcare Week / HIT, Paris  
.....

### 24 May – 25 May 2019

HISTOLOGICA, Oberhausen

### 29 May – 01 June 2019

German X-ray Congress, Leipzig  
.....

### 13 June – 15 June 2019

Meeting German Society for  
Pathology, Frankfurt

### 13 June – 14 June 2019

OGSV-Kongress, Hafernsee  
.....

### 15 June 2019

Rhein-Ruhr-Symposium, Bochum

# Company Information and Outlook

## Chances and Risks Report

Please refer to the explanations in the Annual Report of 31 December 2018 for information about the essential chances and risks in the development of NEXUS Group. There have been no essential changes in the meantime.

## Directors' Holdings

The director's holders of the Supervisory Board and the Executive Board are as follows on 31 March 2019 in comparison to the previous year: cf. Table.

Supervisory Board	Numbers of stock owned	Numbers of options
Dr. jur. Hans-Joachim König	69,900 Previous year (69,900)	0 Previous year (0)
Prof. Dr. Alexander Pocsay	121,500 Previous year (121,500)	0 Previous year (0)
Prof. Dr. Ulrich Krystek	0 Previous year (0)	0 Previous year (0)
Wolfgang Dörflinger	0 Previous year (0)	0 Previous year (0)
Gerald Glasauer	0 Previous year (0)	0 Previous year (0)
Prof. Dr. med Felicia M. Rosenthal	520 Previous year (520)	0 Previous year (0)

Executive Board	Numbers of stock owned	Numbers of options
Dr. Ingo Behrendt	99,900 Previous year (111,900)	0 Previous year (0)
Ralf Heilig	127,650 Previous year (127,650)	0 Previous year (0)
Edgar Kuner	240,351 Previous year (240,351)	0 Previous year (0)

## Outlook: Take Advantage of Momentum

We were also able to start in an extremely positive way in 2019. A sales increase of approx. 11% and an increase in earnings before interest and taxes (EBIT) of approx. 18% as well as a high operating cash flow of approx. € 26.2 million represent a great start into the current year. We were able to continue the positive development of the past years unabated. With the ONE/NEXUS project, we are in the process of creating the organizational and sales prerequisites for the coming years.

However, we must not be content with looking inward. Our customers and competitors are currently developing digitalization and product strategies for the coming years. Previous technology and application decisions are being challenged in this process and market strategies fundamentally reconsidered. This exciting phase provides us with numerous opportunities, for which we must prepare ourselves very carefully and take advantage of opportunities.

We have a right to be optimistic. Thanks to our highly differentiated and innovative product portfolio and a good European presence, we have a very attractive position on the market. NEXUS can also draw on considerable potential in changing market situations. However, we have to prove this anew every day. We can only continue our previous path of success if we constantly increase growth and performance.

The NEXUS team is looking forward to these challenges.

## Accounting and Valuation Methods

This interim report of the NEXUS Group of 31 March 2019 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretations of the International Financial Reporting Interpretation Committee (IFRIC) have been taken into account.

The regulations of IAS 34 were observed in the interim report of 31 March 2019. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Notes to the Group Financial Statement 2018. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2018. The report has not been audited.



# ONE / NEXUS

Digitalization of endoscopic diagnostics



Endoscopy  
(E&L)




Terminology



AEMP  
for endoscopes



PACS  
(CHILI)



Device connection  
(Integrationsserver)

NEXUS / ENDOSCOPY<sup>NG</sup> (E&L) is already the market-leading software solution today thanks to intelligent diagnosis, automatic endoscope detection and washing machine integration. Within the framework of ONE / NEXUS, we extend the range with further process innovations such as CHILI PACS<sup>NG</sup> for qualified image analysis and new terminology integration.

# ONE NEXUS

# GROUP PROFIT AND LOSS ACCOUNT

FOR THE PERIOD FROM  
01 JANUARY TO 31 MARCH 2019 AND 2018

	01/01-31/03/2019	01/01-31/03/2018
	KEUR	KEUR
Revenue	35,465	32,044
Development work capitalized	905	1,171
Other operating income	2,413	661
Cost of materials including purchased services	5,225	5,824
Personnel costs	22,243	18,609
Depreciation	3,666	2,499
Other operating expenses	3,767	3,651
<b>OPERATING RESULT</b>	<b>3,882</b>	<b>3,293</b>
Finance Income	25	35
Finance Expenses	84	75
<b>RESULT BEFORE TAX ON PROFIT</b>	<b>3,823</b>	<b>3,253</b>
Taxes on profit	968	742
<b>CONSOLIDATED SURPLUS</b>	<b>2,855</b>	<b>2,511</b>
Of the consolidated surplus, accounted to:		
- Stockholders of NEXUS AG	2,810	2,601
- Shares of non-controlling partners	45	-90
<b>CONSOLIDATED NET EARNINGS PER SHARE IN EUR</b>		
Weighted average (undiluted/diluted) of issued shares in circulation (in thousands)	15,715 / 15,715	15,724 / 15,724
Undiluted / diluted	0.18 / 0.18	0.17 / 0.17

# GROUP STATEMENT OF CONSOLIDATED INCOME

FOR THE PERIOD FROM  
01 JANUARY TO 31 MARCH 2019 AND 2018

	01/01-31/03/2019	01/01-31/03/2018
	KEUR	KEUR
<b>Consolidated surplus</b>	<b>2,855</b>	<b>2,511</b>
<b>Positions, which are reclassified in profit or loss</b>		
Currency conversion differences	-191	-674
Interest effect from IFRS 9	-49	-
<b>OTHER OVERALL RESULT</b>	<b>-240</b>	<b>-674</b>
<b>OVERALL RESULT OF THE PERIOD</b>	<b>2,615</b>	<b>1,837</b>
<b>Of the overall result of the period, accounted to:</b>		
- Stockholders of NEXUS AG	2,567	1,931
- Shares of non-controlling partners	48	-94

# CONSOLIDATED BALANCE SHEET

AS OF 31 MARCH 2019 AND 31 DECEMBER 2018

ASSETS	31/03/2019	31/12/2018
<b>LONG-TERM ASSETS</b>	<b>KEUR</b>	<b>KEUR</b>
Goodwill	72,893	73,462
Other intangible assets	37,313	38,609
Fixed (Intangible) assets	10,337	10,378
Rights of use of leased assets	8,594	-
Shares in companies valued at equity	26	26
Deferred tax assets	3,409	3,860
Other financial assets	363	156
<b>Total of Long-Term Assets</b>	<b>132,935</b>	<b>126,491</b>
<b>SHORT-TERM ASSETS</b>		
Inventories	599	536
Trade receivables and other receivables	29,896	25,980
Leasing liabilities	1,078	1,007
Receivables from tax on profits	2,394	1,511
Other non-financial assets	5,190	1,918
Other financial assets	1,199	27,249
Short-term financial assets	1,610	1,586
Cash and balance in bank	49,834	25,430
<b>Total of Short-Term Assets</b>	<b>91,800</b>	<b>85,217</b>
<b>Balance Sheet Total</b>	<b>224,735</b>	<b>211,708</b>

EQUITY AND LIABILITIES	31/03/2019	31/12/2018
<b>EQUITY CAPITAL</b>	<b>KEUR</b>	<b>KEUR</b>
Subscribed capital	15,752	15,752
Capital reserves	34,166	34,166
Retained earnings	62,142	52,182
Consolidated surplus	2,810	10,921
Other cumulated Group result	-4,834	-4,640
Own shares	-73	-759
<b>EQUITY CAPITAL ATTRIBUTABLE TO STOCKHOLDERS OF THE PARENT COMPANY</b>	<b>109,963</b>	<b>107,622</b>
Shares of non-controlling partners	751	703
<b>Total Equity Capital</b>	<b>110,714</b>	<b>108,325</b>
<b>LONG-TERM DEBTS</b>		
Pension obligations	10,888	10,838
Deferred tax liabilities	7,101	7,219
Other financial debts	19,397	19,358
Leasing liabilities	5,318	-
<b>Total of Long-Term Debts</b>	<b>42,704</b>	<b>37,415</b>
<b>SHORT-TERM DEBTS</b>		
Accruals	12,263	13,128
Financial liabilities	0	9,000
Trade accounts payable	5,372	7,070
Liabilities from tax on profit	1,604	1,615
Deferred revenue	24,234	4,660
Other non-financial debts	4,607	3,111
Contract liabilities	5,257	5,399
Leasing liabilities	3,291	-
Other financial debts	14,689	21,985
<b>Total of Short-Term Debts</b>	<b>71,317</b>	<b>65,968</b>
<b>Balance Sheet Total</b>	<b>224,735</b>	<b>211,708</b>

# CONSOLIDATED CASH FLOW STATEMENT

FOR THE PERIOD FROM  
01 JANUARY TO 31 MARCH 2019 AND 2018

	2019	2018
	KEUR	KEUR
<b>1. CASH FLOW FROM CURRENT BUSINESS TRANSACTIONS</b>		
Group annual result before tax on income	3,823	3,253
Write-offs (+) / write-ups (-) on intangible assets, tangible assets and financial assets	3,642	2,499
Other expenses not affecting payment (+) / revenue (-)	-111	-1,797
Increase (-) / decrease (+) in inventories	-63	-30
Gain (-) / loss (+) on disposal of fixed assets and securities	26	30
Increase (-) / decrease (+) in receivables and other assets from operating activities	18,610	-7,139
Increase (+) / decrease (-) of accruals insofar as not entered in other comprehensive income	-746	-982
Increase (+) / decrease (-) in liabilities from operating activities	2,698	22,051
Paid interest (-)	-84	-11
Received interest (+)	1	35
Taxes on profit paid (-)	-1,677	-624
Taxes on profit received (+)	114	0
	<b>26,233</b>	<b>17,285</b>
<b>2. CASH FLOW FROM INVESTMENT ACTIVITIES</b>		
Payments (-) / receipts (+) from the acquisition/disposal of intangible and fixed assets	-924	-2,085
Payments (-) for the acquisition of companies consolidated minus cash acquired	0	-3,828
	<b>-924</b>	<b>-5,913</b>
<b>3. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Share issue (-) as part of stock-based compensation	0	-351
(not affecting payment) Adjustment from the application of IFRS 9	-43	-
Payments (-) for the repayment of lease liabilities	-447	-
Payments (-) for the acquisition of own shares	-282	-15
Receipts (+) from the sale of own shares	56	0
	<b>-716</b>	<b>-366</b>
Cash relevant changes in cash and cash equivalents (sum of 1 + 2 + 3)	24,593	11,006
Exchange rate changes on cash and cash equivalents	-189	-768
Cash and cash equivalents at beginning of period	25,430	26,536
Cash and cash equivalents at end of period	<b>49,834</b>	<b>36,774</b>
<b>COMPOSITION OF CASH AND CASH EQUIVALENTS</b>		
Liquid funds	49,834	36,774
Bank liabilities due on demand	0	0
	<b>49,834</b>	<b>36,774</b>

# GROUP STATEMENT OF CHANGES IN EQUITY

## AS OF 31 MARCH 2019 AND 31 MARCH 2018

	Subscribed capital	Capital reserves	Retained earnings	Annual Net Profit	Equity capital difference from currency conversion	Pension reserves	Own shares	Equity capital attributable to stock of parent company	Shares of non-controlling partners	Equity capital total	Authorized Capital
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
<b>CONSOLIDATED EQUITY AS OF 01/01/2018</b>	15,752	34,953	48,202	9,832	889	-7,093	-419	102,116	893	103,009	2,984
Adaptation of the initial application of IFRS 9			-103					-103	0	-103	
Adaptation of the initial application of IFRS 15			6					6	0	6	
<b>ADJUSTED GROUP EQUITY AS OF 1 JANUARY 2018</b>	15,752	34,953	48,105	9,832	889	-7,093	-419	102,019	893	102,912	2,984
Posting of consolidated surplus 2017 in the Group profit carried forward			9,832	-9,832				0		0	
Currency differences					-160	-510		-670	-4	-674	
<b>OTHER COMPREHENSIVE INCOME AFTER TAXES 31 MARCH 2018</b>	0	0	0	0	-160	-510	0	-670	-4	-674	0
Consolidated surplus 3M-2018				2,601				2,601	-90	2,511	
<b>OVERALL RESULT OF THE PERIOD</b>	0	0	0	2,601	-160	-510	0	1,931	-94	1,837	0
Purchase of own shares							-396	-396		-396	
Sale and issue of own shares in the form of share-based payment		-381					411	30		30	
<b>CONSOLIDATED EQUITY AS OF 31 MARCH 2018</b>	15,752	34,572	58,034	2,601	729	-7,603	-404	103,681	799	104,480	2,968
<b>CONSOLIDATED EQUITY AS OF 01 JANUARY 2019</b>	15,752	34,166	52,182	10,921	1,131	-5,771	-759	107,622	703	108,325	2,984
Posting of consolidated surplus 2018 in the Group profit carried forward			10,921	-10,921				0		0	
Adaptation of the application of IFRS 9			-49					-49		-49	
Currency differences			0	0	-147	-47		-194	3	-191	
<b>OTHER COMPREHENSIVE INCOME AFTER TAXES</b>	0	0	-49	0	-147	-47	0	-243	3	-240	0
Consolidated surplus 3M-2019				2,810				2,810	45	2,855	
<b>OVERALL RESULT OF THE PERIOD</b>	0	0	-49	2,810	-147	-47	0	2,567	48	2,615	0
Purchase of own shares							-282	-282		-282	
Sale and issue of own shares in the form of share-based payment			-912				968	56	0	56	
<b>CONSOLIDATED EQUITY AS OF 31 MARCH 2019</b>	15,752	34,166	62,142	2,810	984	-5,818	-73	109,963	751	110,714	2,984

## **Declaration according to § 37y No. 1 WpHG**

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Donaueschingen, 03 May 2019

NEXUS AG  
The Executive Board

***nexus / ag***

NEXUS AG, Irmastraße 1, D-78166 Donaueschingen  
Phone +49 771 22960-0, Fax +49 771 22960-226  
[www.nexus-ag.de](http://www.nexus-ag.de), [info@nexus-ag.de](mailto:info@nexus-ag.de)